Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study

Biosimilar drug makers say that the NOR-SWITCH study on switching from Johnson & Johnson’s infliximab to the Celltrion product supports the concept of biosimilarity and proves that they are subject to the same regulatory standards as originators. Originators, meanwhile, want more evidence that switching works.